Published in Nephron on January 01, 1995
A prospective controlled study of kidney donors: baseline and 6-month follow-up. Am J Kidney Dis (2013) 1.55
A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis (2015) 1.48
Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant (2011) 1.01
[Intensive vitamin D supplementation in the treatment of osteoporosis]. Vnitr Lek (2004) 1.41
Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Methods Find Exp Clin Pharmacol (1995) 0.98
Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl (2001) 0.87
Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res (2010) 0.84
Inhibitor(s) of protein synthesis in uremic serum and urine: partial purification and relationship to amino acid transport. Biochem Med (1982) 0.82
Hippurate participates in the correction of metabolic acidosis. Kidney Int Suppl (2001) 0.82
Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women. Physiol Res (1999) 0.82
Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol (1994) 0.82
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl (2001) 0.80
Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res (1998) 0.80
Analytical identity of an inhibitor of sodium transport isolated from human serum and urine. Nephron (1985) 0.80
Plasma tryptophan level in chronic renal failure. Clin Nephrol (1980) 0.79
Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. Nephron (2001) 0.79
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens (2003) 0.79
A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol (1996) 0.78
Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease? Physiol Res (2002) 0.78
The role of magnesium deficiency in insulin resistance: an in vitro study. J Hypertens Suppl (1991) 0.77
Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron (1993) 0.77
A procedure for the isolation of an inhibitor of sodium transport from the urine of uraemic patients. Physiol Bohemoslov (1982) 0.77
Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol (1987) 0.76
Pseudouridine excretion in healthy subjects and its accumulation in renal failure. Nephron (1992) 0.76
Magnesium deficiency impairs rat soleus muscle glucose utilization and insulin sensitivity. Mater Med Pol (1993) 0.76
Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Physiol Res (1999) 0.76
[Effect of coenzyme Q10 in patients with kidney diseases]. Cas Lek Cesk (2001) 0.75
Accumulated end products participate in glucose intolerance and insulin resistance in uremia. Nephron (1993) 0.75
Inhibitor of renal gluconeogenesis (IGN): additional physiological modulator? Int J Biochem (1980) 0.75
Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment. Artif Organs (1981) 0.75
The effect of vitamin D₃ supplementation on intracellular calcium and plasma membrane calcium ATPase activity in early stages of chronic kidney disease. Physiol Res (2014) 0.75
[Improvement in glucose tolerance and insulin sensitivity after a single administration of tolbutamide in hypertensive patients]. Vnitr Lek (1991) 0.75
Effect of hippurate on tissue fatty acid metabolism. Physiol Bohemoslov (1990) 0.75
[Nitric oxide and the kidneys]. Vnitr Lek (2001) 0.75
Lipid peroxidation and nutrition. Physiol Res (2004) 0.75
Metabolic effects of enalapril in the treatment of essential hypertension. Cor Vasa (1992) 0.75
Influence of ACE inhibition on insulin resistance. Nephrol Dial Transplant (1995) 0.75
[Dependence of the level of glucose utilization inhibitor on creatinine clearance]. Cas Lek Cesk (1986) 0.75
[Diuretics in the treatment of hypertension]. Vnitr Lek (1996) 0.75
[Renal clearance of hippurate in persons with chronic renal insufficiency]. Vnitr Lek (1994) 0.75
[Pharmacokinetic modeling in clinical practice: pefloxacin]. Bratisl Lek Listy (1990) 0.75
The synthesis of middle molecular substances in rat tissues: in vitro study. Proc Eur Dial Transplant Assoc (1978) 0.75
[Enalapril in the treatment of nephrogenic hypertension]. Vnitr Lek (1992) 0.75
[Modern diagnosis of energy and nitrogen balance in renal insufficiency]. Bratisl Lek Listy (1984) 0.75
[Prevention and therapy of atherosclerosis]. Bratisl Lek Listy (1996) 0.75
Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy. Kidney Blood Press Res (2000) 0.75
Comparison of creatinine, hippuric acid, 5-hydroxyindoleacetic acid, serotonin, and pseudouridine concentrations in blood withdrawn from vein and arteriovenous fistula of uremic patients on maintenance hemodialysis. Artif Organs (1991) 0.75
Metabolic actions of middle molecules. Artif Organs (1981) 0.75
[The informational value of creatinine determination]. Cas Lek Cesk (1986) 0.75
Membrane plasmapheresis raises the serum concentrations of pseudouridine. Int J Artif Organs (1991) 0.75
[The effect of acidification and alkalization on hippuran excretion]. Bratisl Lek Listy (1988) 0.75
[Prevention of progression in nephropathies]. Bratisl Lek Listy (1994) 0.75
[Treatment of renal hypertension]. Vnitr Lek (2000) 0.75
[Does therapeutic membrane plasmapheresis increase protein synthesis?]. Cas Lek Cesk (1992) 0.75
[Pharmacodynamics of angiotensin-converting enzyme inhibitors]. Vnitr Lek (1996) 0.75
[Relation between blood glucose and insulin in hemodialysis]. Bratisl Lek Listy (1993) 0.75
[The effect of dipyridamole on hippurate excretion in healthy volunteers and in patients with renal insufficiency]. Cas Lek Cesk (1991) 0.75
Inhibition of glucose uptake by 5-hydroxyindoleacetic acid in the isolated rat soleus muscle. Int Urol Nephrol (1996) 0.75
[Serum hippurate levels in patients with liver cirrhosis under basal conditions and after glucose administration]. Bratisl Lek Listy (1989) 0.75
[Pharmacokinetic aspects of therapy with methenamine hippurate]. Cas Lek Cesk (1987) 0.75
[The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program]. Cas Lek Cesk (1983) 0.75
[Nephrologic manifestations of mitochondrial diseases]. Cas Lek Cesk (2000) 0.75
[Nutritional status of patients before kidney transplantation]. Vnitr Lek (1984) 0.75
Isolation of an additional inhibitor of glucose utilization in renal insufficiency: pseudouridine. J Chromatogr (1990) 0.75
P-aminohippurate accumulation in kidney cortex slices: stimulation by dicarboxylates, amino acids and their oxoanalogues. Physiol Res (1991) 0.75
[Nephrogenic metabolic acidosis]. Vnitr Lek (2003) 0.75
Pathogenesis of metabolic alterations in renal failure. Czech Med (1984) 0.75
[New perspectives of treatment of osteoporosis with thiazides]. Vnitr Lek (1999) 0.75
[Lisinopril in the monotherapy of patients with essential hypertension: the effect of therapy on glucose and lipid metabolism]. Cas Lek Cesk (1993) 0.75
Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage. Prostaglandins Leukot Essent Fatty Acids (1998) 0.75
[Bopindolol does not affect normal glucose and lipid metabolism in hypertensive patients]. Vnitr Lek (1989) 0.75
Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease. Int Urol Nephrol (1997) 0.75
[The role of hippurate in kidney failure]. Ter Arkh (1992) 0.75
[Diuretics in the treatment of hypertension]. Vnitr Lek (1993) 0.75
Erythrocyte transport of middle molecular substances. Proc Eur Dial Transplant Assoc (1981) 0.75
The utilization of glucose in the brain slices during uraemia. Int Urol Nephrol (1974) 0.75
Modulators and mediators of kidney disease progression: new targets of prevention and treatment. Bratisl Lek Listy (1997) 0.75
[Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?]. Cas Lek Cesk (1984) 0.75
[Celiprolol improves glucose metabolism in essential hypertension]. Vnitr Lek (1998) 0.75
[Pefloxacin in the treatment of recurrent urinary tract infections]. Cas Lek Cesk (1990) 0.75
The prevalence of insulin resistance in essential hypertension. Cor Vasa (1993) 0.75
Can plasma concentration of middle molecules contribute to assessment of adequate dialysis treatment? Artif Organs (1986) 0.75
[Hippuran does not interfere with glucose metabolism and proximal tubule function in persons with normal renal function]. Cas Lek Cesk (1988) 0.75
Essential hypertension and insulin resistance. Cor Vasa (1991) 0.75
[Insulin resistance in essential and nephrogenic hypertension]. Cas Lek Cesk (1994) 0.75
Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk. Mutagenesis (2004) 0.75
[Clinico-pharmacologic possibilities of theophylline therapy]. Vnitr Lek (1987) 0.75
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. J Cardiovasc Pharmacol (2001) 0.75
[The primary importance of the kidneys in the development of essential hypertension]. Vnitr Lek (1993) 0.75
[Insulin resistance: its clinical importance and trends in modern research]. Bratisl Lek Listy (1994) 0.75
[The role of thromboxane in the pathogenesis of nephropathies]. Vnitr Lek (1996) 0.75
Middle molecular substances in acute renal failure. Int Urol Nephrol (1982) 0.75
[The effect of a single administration of magnesium sulfate on glucose tolerance and insulinemia in healthy volunteers]. Cas Lek Cesk (1991) 0.75
Serum ex vivo lipoprotein oxidizability in patients with ischemic heart disease supplemented with vitamin E. Physiol Res (2002) 0.75
[Metabolic changes in chronic kidney failure]. Bratisl Lek Listy (1978) 0.75